Medications for Pre Bcell Acute Lymphoblastic Leukemia

1 result
  • besponsa

    (inotuzumab ozogamicin)
    Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
    BESPONSA is indicated for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients aged 1 year and older.